ADMA BIOLOGICS, INC. Increase (Decrease) in Other Current Liabilities
ADMA BIOLOGICS, INC. (ADMA) reported Increase (Decrease) in Other Current Liabilities of -$33.41 thousand for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-12.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherCurrentLiabilities · last filed 2021-05-12
- ADMA BIOLOGICS, INC. increase (decrease) in other current liabilities for the quarter ending 2021-03-31 was -$33.41K.
- ADMA BIOLOGICS, INC. increase (decrease) in other current liabilities for the quarter ending 2020-12-31 was -$22.14K.
- ADMA BIOLOGICS, INC. increase (decrease) in other current liabilities for the quarter ending 2020-09-30 was -$20.18K.
- ADMA BIOLOGICS, INC. increase (decrease) in other current liabilities for the quarter ending 2020-06-30 was -$46.19K.
- ADMA BIOLOGICS, INC. increase (decrease) in other current liabilities for fiscal 2020 was -$134.39K.
- ADMA BIOLOGICS, INC. increase (decrease) in other current liabilities for fiscal 2019 was -$190.51K.
- ADMA BIOLOGICS, INC. increase (decrease) in other current liabilities for fiscal 2017 was -$11.82K.
- ADMA BIOLOGICS, INC. increase (decrease) in other current liabilities for fiscal 2016 was -$30.56K.
| Period end | Increase (Decrease) in Other Current Liabilities 3 month | Increase (Decrease) in Other Current Liabilities 6 month | Increase (Decrease) in Other Current Liabilities 9 month | Increase (Decrease) in Other Current Liabilities 12 month |
|---|---|---|---|---|
| 2021-03-31 | -$33.41K 10-Q · filed 2021-05-12 | -$55.56K derived: sum of 2 quarters · filed 2021-05-12 | -$75.74K derived: sum of 3 quarters · filed 2021-05-12 | -$121.92K derived: sum of 4 quarters · filed 2021-05-12 |
| 2020-12-31 | -$22.14K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$42.32K derived: sum of 2 quarters · filed 2021-03-25 | -$88.51K derived: sum of 3 quarters · filed 2021-03-25 | -$134.39K 10-K · filed 2021-03-25 |
| 2020-09-30 | -$20.18K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$66.36K derived: sum of 2 quarters · filed 2020-11-05 | -$112.25K 10-Q · filed 2020-11-05 | -$164.84K derived: sum of 4 quarters · filed 2021-05-12 |
| 2020-06-30 | -$46.19K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | -$92.07K 10-Q · filed 2020-08-05 | -$144.66K derived: sum of 3 quarters · filed 2021-05-12 | -$191.55K derived: sum of 4 quarters · filed 2021-05-12 |
| 2020-03-31 | -$45.88K 10-Q · filed 2021-05-12 | -$98.48K derived: sum of 2 quarters · filed 2021-05-12 | -$145.37K derived: sum of 3 quarters · filed 2021-05-12 | -$165.95K derived: sum of 4 quarters · filed 2021-05-12 |
| 2019-12-31 | -$52.60K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$99.48K derived: sum of 2 quarters · filed 2021-03-25 | -$120.07K derived: sum of 3 quarters · filed 2021-03-25 | -$190.51K 10-K · filed 2021-03-25 |
| 2019-09-30 | -$46.89K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$67.47K derived: sum of 2 quarters · filed 2020-11-05 | -$137.92K 10-Q · filed 2020-11-05 | |
| 2019-06-30 | -$20.59K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | -$91.03K 10-Q · filed 2020-08-05 | ||
| 2019-03-31 | -$70.44K 10-Q · filed 2020-05-06 | |||
| 2018-09-30 | -$59.36K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | -$16.34K derived: sum of 2 quarters · filed 2019-11-06 | $191.39K 10-Q · filed 2019-11-06 | $183.35K derived: sum of 4 quarters · filed 2019-11-06 |
| 2018-06-30 | $43.02K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $250.75K 10-Q · filed 2019-08-08 | $242.71K derived: sum of 3 quarters · filed 2019-08-08 | $254.22K derived: sum of 4 quarters · filed 2019-08-08 |
| 2018-03-31 | $207.74K 10-Q · filed 2019-05-08 | $199.69K derived: sum of 2 quarters · filed 2019-05-08 | $211.20K derived: sum of 3 quarters · filed 2019-05-08 | $203.56K derived: sum of 4 quarters · filed 2019-05-08 |
| 2017-12-31 | -$8.04K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-29 | $3.46K derived: sum of 2 quarters · filed 2018-11-09 | -$4.18K derived: sum of 3 quarters · filed 2018-11-09 | -$11.82K 10-K · filed 2018-03-29 |
| 2017-09-30 | $11.51K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $3.87K derived: sum of 2 quarters · filed 2018-11-09 | -$3.77K 10-Q · filed 2018-11-09 | -$11.41K derived: sum of 4 quarters · filed 2018-11-09 |
| 2017-06-30 | -$7.64K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-10 | -$15.28K 10-Q · filed 2018-08-10 | -$22.92K derived: sum of 3 quarters · filed 2018-08-10 | -$30.56K derived: sum of 4 quarters · filed 2018-08-10 |
| 2017-03-31 | -$7.64K 10-Q · filed 2018-05-14 | -$15.28K derived: sum of 2 quarters · filed 2018-05-14 | -$22.92K derived: sum of 3 quarters · filed 2018-05-14 | |
| 2016-12-31 | -$7.64K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-29 | -$15.28K derived: sum of 2 quarters · filed 2018-03-29 | -$30.56K 10-K · filed 2018-03-29 | |
| 2016-09-30 | -$7.64K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | -$22.92K 10-Q · filed 2017-11-03 | ||
| 2016-06-30 | -$15.28K 10-Q · filed 2017-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |